Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …
infected and nearly six million dead worldwide, making it the most significant pandemic …
Optimization of anti-SARS-CoV-2 neutralizing antibody therapies: roadmap to improve clinical effectiveness and implementation
K van der Straten, MJ van Gils, SW de Taeye… - Frontiers in Medical …, 2022 - frontiersin.org
One of the major breakthroughs to combat the current Coronavirus Disease 2019 (COVID-
19) pandemic has been the development of highly effective vaccines against the Severe …
19) pandemic has been the development of highly effective vaccines against the Severe …
[HTML][HTML] Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2
Antibodies capable of neutralizing SARS-CoV-2 are well studied, but Fc receptor–
dependent antibody activities that can also significantly impact the course of infection have …
dependent antibody activities that can also significantly impact the course of infection have …
Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
M Takeshita, H Fukuyama, K Kamada, T Matsumoto… - Iscience, 2022 - cell.com
The use of therapeutic neutralizing antibodies against SARS-CoV-2 infection has been
highly effective. However, there remain few practical antibodies against viruses that are …
highly effective. However, there remain few practical antibodies against viruses that are …
Antibody-mediated immunity to SARS-CoV-2 spike
Despite effective spike-based vaccines and monoclonal antibodies, the SARS-CoV-2
pandemic continues more than two and a half years post-onset. Relentless investigation has …
pandemic continues more than two and a half years post-onset. Relentless investigation has …
Hybrid immunity elicits potent cross-variant ADCC against SARS-CoV-2 through a combination of anti-S1 and S2 antibodies
Antibodies capable of neutralising SARS-CoV-2 have been well studied, but the Fc receptor-
dependent antibody activities that also significantly impact the course of infection have not …
dependent antibody activities that also significantly impact the course of infection have not …
Antibodies, B Cell Responses and Immune Responses to SARS-CoV-2 Infections
L Martinez-Sobrido, JJ Kobie - Antibodies, 2023 - mdpi.com
Coronaviruses (CoV) are enveloped, positive-sense, single-stranded RNA viruses
responsible for causing seasonal, mild respiratory disease in humans [1, 2]. They include …
responsible for causing seasonal, mild respiratory disease in humans [1, 2]. They include …
Isolation of SARS-CoV-2-blocking recombinant antibody fragments and characterisation of their binding to variant spike proteins
D Antoine, M Mohammadi, CE McDermott… - Frontiers in …, 2022 - frontiersin.org
COVID-19 is a severe acute respiratory disease caused by SARS-CoV-2. From its initial
appearance in Wuhan, China in 2019, it developed rapidly into a global pandemic. In …
appearance in Wuhan, China in 2019, it developed rapidly into a global pandemic. In …
Fc-modified SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
M Takeshita, H Fukuyama, K Kamada, T Matsumoto… - bioRxiv, 2022 - biorxiv.org
The use of therapeutic neutralizing antibodies against SARS-CoV-2 infection has been
highly effective. However, there remain few practical antibodies against viruses that are …
highly effective. However, there remain few practical antibodies against viruses that are …
Expression of monoclonal antibodies for functional and structural studies
V Irani, C Soliman, MA Raftis, AJ Guy, A Elbourne… - Methods in …, 2022 - Elsevier
Monoclonal antibodies are a mainstay of the research laboratory, with increasing focus on
human IgG that best reflects the human antibody response and allows swift transition to …
human IgG that best reflects the human antibody response and allows swift transition to …